Discovery of Allosteric MEK Inhibitors

Kinase Inhibitor Drugs

Volumn , Issue , 2009, Pages 229-252

  Wallace, Eli ^a   Blake, James F ^a  

^a ARRAY BIOPHARMA INC   (United States)

Author keywords

Allosteric MEK inhibitor discovery; Preclinical pharmacokinetics of AZD 6244; Pyridone MEK inhibitors

Indexed keywords

EID: 79959456529     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9780470524961.ch9     Document Type: Chapter

References (62)

1. Adjei, A. A., Cohen, R. B., Franklin, W., et al. (2008). Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 26 (13), 2139-2146.
2. Agarwal, R., Banerji, U., Camidge, D., et al. (2008). The first-in-human study of the solid oral dosage form of AZD6244 (ARRY-142886): a Phase I trial in patients (pts) with advanced cancer. J Clin Oncol. 26 (May 20 Suppl), Abst 3535.
3. Alessi, D. R., Cuenda, A., Cohen, P., et al. (1995). PD098059 is a specific inhibitor of the activation of mitogen-activated protein kinase kinase in vitro and in vivo. J Biol Chem. 270 (46), 27489-27494.
4. Auffinger, P., Hays, F. A., Westhof, E., et al. (2004). Halogen bonds in biological molecules. Proc Natl Acad Sci USA. 101 (48), 16789-16794.
5. Belanger, L. F., Roy, S., Tremblay, M., et al. (2003). Mek2 is dispensable for mouse growth and development. Mol Cell Biol. 23 (14), 4778-4787.
6. Bos, J. L. (1989). ras Oncogenes in human cancer: a review. Cancer Res. 49 (17), 4682-4689.
7. Carter, L., Brown, S., Klopfenstein, N., et al. (2008). ARRY-162, a novel inhibitor of MEK kinase: Phase 1A-1B pharmacokinetic and pharmacodynamic results. Ann Rheum Dis. 67 (Suppl II), 87.
8. Cervantes, A., Macarulla, T., Martinelli, E., et al. (2008). Correlation of KRAS status (wild type [wt] vs. mutant [mt]) with efficacy to first-line cetuximab in a study of cetuximab single agent followed by cetuximab + FOLFIRI in patients (pts) with metastatic colorectal cancer (mCRC). J Clin Oncol. 26 (May 20 suppl; Abst 4129).
9. Chang, H. J., Park, J. S., Kim, M. H., et al. (2006). Extracellular signal-regulated kinases and AP-1 mediate the up-regulation of vascular endothelial growth factor by PDGF in human vascular smooth muscle cells. Int J Oncol. 28 (1), 135-141.
10. Cohen, Y., Xing, M., Mambo, E., et al. (2003). BRAF mutation in papillary thyroid carcinoma. J Natl Cancer Inst. 95 (8), 625-627.
11. Davies, B. R., Logie, A., McKay, J. S., et al. (2007). AZD6244 (ARRY-142886), a potent inhibitor of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase 1/2 kinases: mechanism of action in vivo, pharmacokinetic/pharmacodynamic relationship, and potential for combination in preclinical models. Mol Cancer Ther. 6 (8), 2209-2219.
12. Davies, H., Bignell, G. R., Cox, C., et al. (2002). Mutations of the BRAF gene in human cancer. Nature. 417 (6892), 949-954.
13. Dhillon, A. S., Hagan, S., Rath, O., et al. (2007). MAP kinase signalling pathways in cancer. Oncogene. 26 (22), 3279-3290.
14. Doyle, M., Yeh, T., Brown, S., et al. (2005). Validation and use of a biomarker for clinical development of the MEK1/2 inhibitor ARRY-142886 (AZD6244). J Clin Oncol. 23 (16 S, Part I of II (June 1 Suppl)), 3075.
15. Dry, J., Harbron, C., Hickinson, M., et al. (2008). Biologically driven interpretation reveals molecular signatures predictive of oncogenic addiction to MEK signaling and cell line response to the MEK1/2 inhibitor AZD6244 (ARRY-142886). Proc Am Assoc Cancer Res. 49, Abst 913.
16. Dudley, D. T., Pang, L., Decker, S. J., et al. (1995). A synthetic inhibitor of the mitogen-activated protein kinase cascade. Proc Natl Acad Sci USA. 92 (17), 7686-7689.
17. Dummer, R., Robert, C., Chapman, P., et al. (2008). AZD6244 (ARRY-142886) vs temozolomide (TMZ) in patients (pts) with advanced melanoma: an open-label, randomized, multicenter, Phase II study. J Clin Oncol. 26 (May 20 Suppl), Abst 9033.
18. Duncia, J. V., Santella, J. B. 3rd, Higley, C. A., et al. (1998). MEK inhibitors: the chemistry and biological activity of U0126, its analogs, and cyclization products. Bioorg Med Chem Lett. 8 (20), 2839-2844.
19. Favata, M. F., Horiuchi, K. Y., Manos, E. J., et al. (1998). Identification of a novel inhibitor of mitogen-activated protein kinase kinase. J Biol Chem. 273 (29), 18623-18632.
20. Friesner, R. A., Banks, J. L., Murphy, R. B., et al. (2004). Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy. J Med Chem. 47 (7), 1739-1749.
21. Giroux, S., Tremblay, M., Bernard, D., et al. (1999). Embryonic death of Mek1-deficient mice reveals a role for this kinase in angiogenesis in the labyrinthine region of the placenta. Curr Biol. 9 (7), 369-372.
22. Halgren, T. A., Murphy, R. B., Friesner, R. A., et al. (2004). Glide: a new approach for rapid, accurate docking and scoring. 2. Enrichment factors in database screening. J Med Chem. 47 (7), 1750-1759.
23. Hanahan, D., and Weinberg, R. A. (2000). The hallmarks of cancer. Cell. 100 (1), 57-70.
24. Hoshino, R., Chatani, Y., Yamori, T., et al. (1999). Constitutive activation of the 41-/43-kDa mitogen-activated protein kinase signaling pathway in human tumors. Oncogene. 18 (3), 813-822.
25. Jaffee, B. D., Manos, E. J., Collins, R. J., et al. (2000). Inhibition of MAP kinase kinase (MEK) results in an anti-inflammatory response in vivo. Biochem Biophys Res Commun. 268 (2), 647-651.
26. Ji, R. R., Befort, K., Brenner, G. J., et al. (2002). ERK MAP kinase activation in superficial spinal cord neurons induces prodynorphin and NK-1 upregulation and contributes to persistent inflammatory pain hypersensitivity. J Neurosci. 22 (2), 478-485.
27. Jung, Y. D., Nakano, K., Liu, W., et al. (1999). Extracellular signal-regulated kinase activation is required for up-regulation of vascular endothelial growth factor by serum starvation in human colon carcinoma cells. Cancer Res. 59 (19), 4804-4807.
28. Kaufman, M. D., Barrett, S. D., Flamme, C. M., et al. (2004). Synthesis and SAR development of PD0325901, a potent and highly bioavailable MEK inhibitor. Proc Am Assoc Cancer Res. 45, Abst 2477.
29. Khambata-Ford, S., Garrett, C. R., Meropol, N. J., et al. (2007). Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab. J Clin Oncol. 25 (22), 3230-3237.
30. Koch, K. (2006). ARRY-438162, a selective, potent inhibitor of MEK 1/2 in clinical development for the treatment of inflammatory disease. Presented at the 14th International Inflammation Research Association Conference, Cambridge, MD.
31. Lang, I., Adenis, A., Boer, K., et al. (2008). AZD6244 (ARRY-142886) versus capecitabine (CAP) in patients (pts) with metastatic colorectal cancer (mCRC) who have failed prior chemotherapy. J Clin Oncol. 26 (May 20 Suppl), Abst 4114.
32. Lee, P., Wallace, E., Yeh, T., et al. (2004). ARRY-142886, a potent and selective MEK inhibitor: III. Efficacy against human xenograft models correlates with decreased ERK phosphorylaiton. Proc Am Assoc Cancer Res. 45, Abst 3890.
33. LoRusso, P. M., Adjei, A. A., Varterasian, M., et al. (2005). Phase I and pharmacodynamic study of the oral MEK inhibitor CI-1040 in patients with advanced malignancies . J Clin Oncol. 23 (23), 5281-5293.
34. Ma, W., and Quirion, R. (2005). The ERK/MAPK pathway, as a target for the treatment of neuropathic pain. Expert Opin Ther Targets. 9 (4), 699-713.
35. Marks, J. L., Gong, Y., Chitale, D., et al. (2008). Novel MEK1 mutation identified by mutational analysis of epidermal growth factor receptor signaling pathway genes in lung adenocarcinoma. Cancer Res. 68 (14), 5524-5528.
36. Meloche, S., and Pouyssegur, J. (2007). The ERK1/2 mitogen-activated protein kinase pathway as a master regulator of the G1-to S-phase transition. Oncogene. 26 (22), 3227-3239.
37. Miller, V. A., Riely, G. J., Zakowski, M. F., et al. (2008). Molecular characteristics of bronchioloalveolar carcinoma and adenocarcinoma, bronchioloalveolar carcinoma subtype, predict response to erlotinib. J Clin Oncol. 26 (9), 1472-1478.
38. Minino, A. M., Heron, M. P., Murphy, S. L., et al. (2007). Deaths: final data for 2004. Natl Vital Stat Rep. 55 (19), 1-119.
39. Muller, K., Faeh, C., and Diederich, F. (2007). Fluorine in pharmaceuticals: looking beyond intuition. Science. 317 (5846), 1881-1886.
40. Ohren, J. F., Chen, H., Pavlovsky, A., et al. (2004). Structures of human MAP kinase kinase 1 (MEK1) and MEK2 describe novel noncompetitive kinase inhibition. Nat Struct Mol Biol. 11 (12), 1192-1197.
41. Pelletier, J. P., Fernandes, J. C., Brunet, J., et al. (2003). In vivo selective inhibition of mitogen-activated protein kinase kinase 1/2 in rabbit experimental osteoarthritis is associated with a reduction in the development of structural changes. Arthritis Rheum. 48 (6), 1582-1593.
42. Pickle, L. W., Hao, Y., Jemal, A., et al. (2007). A new method of estimating United States and state-level cancer incidence counts for the current calendar year. CA Cancer J Clin. 57, 30-42.
43. Platanias, L. C. (2003). Map kinase signaling pathways and hematologic malignancies. Blood. 101 (12), 4667-4679.
44. Rinehart, J., Adjei, A. A., LoRusso, P. M., et al. (2004). Multicenter Phase II study of the oral MEK inhibitor, CI-1040, in patients with advanced non-small-cell lung, breast, colon, and pancreatic cancer. J Clin Oncol. 22 (22), 4456-4462.
45. Roberts, P. J., and Der, C. J. (2007). Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer. Oncogene. 26 (22), 3291-3310.
46. Scholl, F. A., Dumesic, P. A., and Khavari, P. A. (2005). Effects of active MEK1 expression in vivo. Cancer Lett. 230 (1), 1-5.
47. Sebolt-Leopold, J. S., Dudley, D. T., Herrera, R., et al. (1999). Blockade of the MAP kinase pathway suppresses growth of colon tumors in vivo. Nat Med. 5 (7), 810-816.
48. Shannon, A., Telfer, B., Babur, M., et al. (2008). Combining the potent MEK1/2 inhibitor AZD6244 (ARRY-142886) with radiotherapy in a lung tumor xenograft model; pharmacodynamic effects, therapeutic benefits and the hypoxia response. Proc Am Assoc Cancer Res. 49, Abst 2568.
49. Tecle, H. (2002). The development of kinase inhibitors with unusual mechanism of action: CI-1040, a selective, non-ATP competitive MEK inhibitor in the clinic. Presented at the IBC 2nd International Conference on Protein Kinases: Target Validation, Drug Discovery and Clinical Development of Kinase Therapeutics, Boston, MA.
50. Thiel, M. J., Schaefer, C. J., Lesch, M. E., et al. (2007). Central role of the MEK/ERK MAP kinase pathway in a mouse model of rheumatoid arthritis: potential proinflammatory mechanisms. Arthritis Rheum. 56 (10), 3347-3357.
51. Turjanski, A. G., Vaque, J. P., and Gutkind, J. S. (2007). MAP kinases and the control of nuclear events. Oncogene. 26 (22), 3240-3253.
52. Tzekova, V., Cebotaru, C., Ciuleanu, T., et al. (2008). Efficacy and safety of AZD6244 (ARRY-142886) as second/third-line treatment of patients (pts) with advanced non-small cell lung cancer (NSCLC). J Clin Oncol. 26 (May 20 Suppl), Abst 8029.
53. Ussar, S., and Voss, T. (2004). MEK1 and MEK2, different regulators of the G1/S transition. J Biol Chem. 279 (42), 43861-43869.
54. Van Custem, E., Lang, I., D'haens, G., et al. (2008). KRAS status and efficacy in the first-line treatment of patients with metastatic colorectal cancer (mCRC) treated with FOLFIRI with or without cetuximab: the CRYSTAL experience. J Clin Oncol. 26 (May 20 Suppl; Abst 2).
55. Wallace, E., Yeh, T., Lyssikatos, J., et al. (2004). Preclinical development of ARRY-142886, a potent and selective MEK inhibitor. Proc Am Assoc Cancer Res. 45, Abst 3891.
56. Wallace, E., Lyssikatos, J., Blake, J., et al. (2005). 4-(4-Bromo-2-fluorophenylamino)-1-methyl-pyridin-2(1H)ones: potent and selective MEK 1,2 inhibitors. Presented at the 17th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, Philadelphia, PA.
57. Wallace, E. M., Lyssikatos, J., Blake, J. F., et al. (2006). Potent and selective mitogen-activated protein kinase kinase (MEK) 1,2 inhibitor. 1. 4-(4-Bromo-2-fluorophenylamino)-1-methylpyridin-2(1 H)-ones. J Med Chem. 49 (2), 441-444.
58. Wang, X., Wang, H., Xu, L., et al. (2003). Significant neuroprotection against ischemic brain injury by inhibition of the MEK1 protein kinase in mice: exploration of potential mechanism associated with apoptosis. J Pharmacol Exp Ther. 304 (1), 172-178.
59. Weinstein, I. B., and Joe, A. (2008). Oncogene addiction. Cancer Res. 68 (9), 3077-3080; discussion 3080.
60. Wilkinson, R., Logie, A., Haupt, N., et al. (2008). Activity of the MEK1/2 inhibitor AZD6244 (ARRY-142886) in combination with standard and approved therapies:impact of in vivo sequencing of drug administration. Proc Am Assoc Cancer Res. 49, Abst 4012.
61. Xu, X., Quiros, R. M., Gattuso, P., et al. (2003). High prevalence of BRAF gene mutation in papillary thyroid carcinomas and thyroid tumor cell lines. Cancer Res. 63 (15), 4561-4567.
62. Yeh, T. C., Marsh, V., Bernat, B. A., et al. (2007). Biological characterization of ARRY-142886 (AZD6244), a potent, highly selective mitogen-activated protein kinase kinase 1/2 inhibitor. Clin Cancer Res. 13 (5), 1576-1583.